[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brugada-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brugada-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,79,130,154,191,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100382312","distribution-of-cell-cell-junction-proteins-in-arrhythmic-disorders-100382312",true,"NCT04257994","Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders","Analysis of Distribution of Cell-cell Junction Proteins in Buccal Smear Samples From Patients With Arrhythmic Disorders and Family Members at Risk as a Means for Diagnosis","Inclusion Criteria:• Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust.\n\n* Family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis. These groups include both individuals with clear disease manifestation (termed \"affected\") as shown by conventional diagnostic approaches (electrocardiography, echocardiography, cardiac MRI, Holter monitoring) as well as potential carriers of disease-causing mutations who, however, may not\u002Fnot yet manifest any overt sign of cardiovascular abnormalities (termed \"carriers\"). These are typically family members of probands diagnosed with a heritable arrhythmic disorder or family members of a sudden cardiac death victim.\n* All individuals that fall in the above categories will be included regardless of their management (medication, devices, and surgical procedures).\n* Individuals with co-existing conditions will also be included and their medical history will be taken into account when interpreting the results of the immunohistochemical analysis.\n* Adult individuals (\\>18 years of age).\n* Pregnant women will be included as the approach used is not in any way harmful or uncomfortable.\n* All individuals must have provided the study team with a signed informed consent in order to participate in the study.\n\nExclusion Criteria:• Children under 18 years of age\n\n* Individuals lacking decisional capacity.\n* Individuals with non-heritable, non-arrhythmic cardiac disorders (such as ischemic heart disease or inflammatory disorders) followed at St. George's University Hospitals NHS Foundation Trust.\n* Non-English speakers will be excluded from the study unless a translator is present who can thoroughly explain to them the research question\u002Fplan in order for them to provide an informed consent.",false,"ALL","18 Years",{"count":20,"type":21},26,"ESTIMATED","OBSERVATIONAL","Every week in the UK, 12 apparently healthy and fit individuals under the age of 35 die suddenly, a tragic event known as sudden cardiac death (SCD). The investigators have shown that heritable cardiac disorders affect the distribution of proteins at the cardiac cell-cell junctions, the areas where cardiac cells are mechanically and electrically coupled. This knowledge has helped the investigators diagnose specific heart disorders in individuals thus reducing the risk and incidence of SCD. Yet, the primary material required is a heart sample. A heart biopsy is an invasive process that comes with risks and is not performed unless absolutely necessary. And it is impossible to obtain a heart sample from an individual that may be carrying a disease-causing mutation (and hence be at risk of SCD) but does not yet show evidence of disease manifestation. The investigators recently showed that buccal cells show changes in protein distribution equivalent to those exhibited by the heart,hence providing them with a surrogate tissue for the myocardium. The investigators aim to use buccal smears as a means to identify those at risk of SCD. Patients regularly seen at the cardiology clinics at St. George's Hospital can participate in the study. The investigators shall take a buccal smear simply by rubbing a soft brush at the inside of their cheek and smearing it on a slide. Most individuals willing to participate in the study will only have to provide the investigators with a sample once. However, in selected cases (for instance, if the patients show disease progression or have a change in medication) they may be asked to provide the investigators with a subsequent sample during one of their scheduled follow-up visits. The process takes only a few seconds, is totally risk- and pain-free and it is anticipated to have great implications in diagnosis and patient management.",[25,26,27],"Arrhythmogenic Right Ventricular Dysplasia","Brugada Syndrome","Cardiac Channelopathy",[29],"cardiac arrhythmias","RECRUITING","2026-05-07",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":34},"2017-10-15",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"St. George's Hospital, London","OTHER",1,{"id":44,"slug":45,"hasResults":16,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":67,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100558055","national-network-for-cardiovascular-genomics-advancing-cardiovascular-healthcare-for-hereditary-diseases-in-brazils-unified-health-system-through-a-multicenter-registry-100558055","NCT06546137","National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","RENOMICA-Hcor","Inclusion Criteria:\n\n* Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines\n* Agree to receive genetic counseling\n* Sign informed consent form\n* Provide the information required in the case report form\n\nExclusion Criteria:\n\n* Signature absent from informed consent form\n* Inadequate buccal swab (sample may be collected twice)",{"count":51,"type":21},1211,"6 Months","The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:\n\nWhich genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.",[55,56,57,25,58,59,60,61,62,63,64,26,65,66],"Cardiomyopathy, Hypertrophic","Cardiomyopathy, Dilated","Cardiomyopathy Restrictive","Non-Compaction Cardiomyopathy","Familial Hypercholesterolemia","Marfan Syndrome","Ehlers-Danlos Syndrome, Vascular Type","Loeys-Dietz Syndrome","Long QT Syndrome","Short Qt Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Sudden Cardiac Death",[68,69],"hereditary cardiovascular diseases","whole genome sequencing","2026-05-04",{"date":33,"type":34},{"date":73,"type":34},"2025-04-30",{"date":75,"type":21},"2026-08-31",{"name":77,"class":41},"Hospital do Coracao",27,{"id":80,"slug":81,"hasResults":16,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":86,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":89,"conditions":90,"keywords":108,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100345304","fetal-electrophysiologic-abnormalities-in-high-risk-pregnancies-associated-with-fetal-demise-100345304","NCT03775954","Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise","Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise","Inclusion Criteria:\n\n* Current pregnancy complicated by one of the five diagnostic categories\n\n  * prior unexplained Stillbirth at\u002Fafter 20 weeks gestation\n  * fetal major congenital heart defect\n  * fetal hydrops\n  * fetal gastroschisis\n  * monochorionic twin pregnancy\n* Subject must be 18 years of age or older\n* Subject must be English speaking and must be able to read and sign the consent form in English\n* Subject must be able to recline comfortably for 1-3 hours\n* Subject must be willing to complete all three procedures (fMCG, fMCG, nECG) as per protocol, unless medically unable\n* Subject must be willing to allow us to review her and her infants prenatal, deliver, and post-natal records to verify diagnosis, and clinical findings.\n\nExclusion Criteria:\n\n* Severe claustrophobia not reduced by taking breaks, or by having the light on, or by having someone in the room with them.\n* Active labor\n* Acute illness\n* Unable to recline comfortably with a pillow for more than 1-3 hours (assuming some breaks are provided)\n* Weight over 450 lbs\n* An electric stimulation device (TENS unit, pacemaker, or nerve stimulator) that could produce electric or magnetic noise.\n\n  * Note that the Tristan 624 Magnetometer does not pose a risk to the subject's device, (since fMCG does not produce any energy or magnetism), but stimulators themselves can cause interference for our recordings. Some devices may still qualify, and discussion with study nurse may be useful if subject has a pacemaker or similar device.\n\nThe subject will have a single 2-3 hour fetal magnetocardiogram at approximately 20 and 27 weeks GA, and again, if medical condition allows, between 30 and 37 weeks GA, then her infant will have an ECG between 0 and 4 weeks of age. Subjects will be paid a nominal fee for their participation each time, as well as transportation reimbursement if \\>25 miles. For subjects traveling a long distance, the ECG may be performed locally or at home.","FEMALE",{"count":88,"type":21},30,"Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden electrophysiologic abnormalities that could lead to fetal demise in five high-risk pregnancy conditions associated with fetal demise.",[91,92,93,94,95,96,97,98,63,99,100,101,102,103,104,105,106,26,107],"High Risk Pregnancy","Congenital Heart Disease","Fetal Hydrops","Twin Monochorionic Monoamniotic Placenta","Gastroschisis","Fetal Demise","Stillbirth","Fetal Arrhythmia","Intrauterine Fetal Death","Sudden Infant Death","Pregnancy Loss","Twin Twin Transfusion Syndrome","Birth Defect","Fetal Cardiac Anomaly","Fetal Cardiac Disorder","Fetal Death","Fetal Tachycardia",[109,97,110,111,112,91,113,114,115,116,117,118,119],"Fetal Magnetocardiography","Intrauterine Fetal Demise","Fetal Heart Rate Variability","Fetal Arrhythmias","Pregnancy","Fetal Anomaly","Fetal Echocardiography","Non-Stress Testing","New Technology","Birth Defects","Fetal Research","2026-03-02",{"date":122,"type":34},"2026-03-04",{"date":124,"type":34},"2018-07-01",{"date":126,"type":21},"2028-11-30",{"name":128,"class":41},"Medical College of Wisconsin",2,{"id":131,"slug":132,"hasResults":16,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":140,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":42},"100488676","brugada-syndrome-substrate-characterization-and-ablation-100488676","NCT05643209","Brugada Syndrome Substrate Characterization and Ablation","Brugada Syndrome Substrate Characterization and Ablation: Insights From ECG BrS Type I Pattern, Novel Prognostic Index dST-Tiso and High Density Mapping","UNCOVERBrS","Inclusion Criteria:\n\n1. Symptomatic patients diagnosed with BrS-ECG pattern of types 1 and 2, both spontaneous and arising after Ajmaline tests, already implanted with an ICD.\n\n   Symptomatic patients are defined as those who present ≥1 documented episode of VT \u002F VF in the 12 months prior to enrollment.\n2. Patients eligible for ablation with 3D high-density mapping system in accordance with national guidelines, IFU and according to medical decision;\n3. Adult patients able to provide written informed consent\n\nExclusion Criteria:\n\n1. Patients unable to provide written informed consent;\n2. Patients unable to guarantee their presence at future FU visits;\n3. Patients who, according to medical judgment, have a life expectancy of less than 12 months;\n4. Patients who have undergone cardiac ablation in the 90 days prior to enrollment.\n5. Patients who have had adverse events that have not been resolved after any invasive procedure;\n6. Women potentially pregnant or planning to become pregnant.",{"count":139,"type":21},20,"INTERVENTIONAL",[142],"NA","Independent, single center, prospective study, to evaluate the efficacy, in consecutive BrS patients undergoing catheter ablation, at medium-long term follow-up after epicardial substrate homogenization. The target area is defined collecting signals using high density and high resolution mapping with equi-spaced electrode array. The ablation of abnormal fragmented prolonged low-frequency ventricular electrograms is performed by contact force catheter.",[26],"2025-08-12",{"date":147,"type":34},"2025-08-15",{"date":149,"type":34},"2023-02-01",{"date":151,"type":21},"2026-06-30",{"name":153,"class":41},"Maria Cecilia Hospital",{"id":155,"slug":156,"hasResults":16,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":164,"studyType":22,"phases":4,"briefSummary":165,"conditions":166,"keywords":175,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",{"count":163,"type":21},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[167,168,169,170,171,25,63,26,172,65,173,174],"Arrhythmias, Cardiac","Atrial Fibrillation","Atrial Flutter","Ventricular Tachycardia","Atrial Tachycardia","Supraventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[176,177,178,179,180,181,174],"Catheter Ablation","Biomarkers","Cardiac Arrhythmia","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":184,"type":34},"2025-03-30",{"date":186,"type":34},"2021-03-17",{"date":188,"type":21},"2031-12-31",{"name":190,"class":41},"Universitätsklinikum Hamburg-Eppendorf",{"id":192,"slug":193,"hasResults":16,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":4},"100584356","dna-methylation-in-brugada-syndrome-and-risk-of-sudden-cardiac-death-100584356","NCT06888271","DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death","DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death (ANDROMEDA)","ANDROMEDA","Inclusion Criteria:\n\n* Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.\n* \\>18 years\n* Unrelated patients\n\nExclusion Criteria:\n\n* Related patients\n* Not type 1 Br patter",{"count":200,"type":21},10,"The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is:\n\nDoes DNA methylation changes distinguish Brugada patients from healthy controls?\n\nDoes DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?",[26,203],"Sudden Cardiac Death Due to Cardiac Arrhythmia",[205,206,207,208],"DNA methylation","Liquid biopsy","Sudden cardiac death","Brugada syndrome","NOT_YET_RECRUITING","2025-03-20",{"date":212,"type":34},"2025-03-24",{"date":214,"type":21},"2025-05",{"date":216,"type":21},"2026-07",{"name":218,"class":41},"University of Campania Luigi Vanvitelli",{"id":220,"slug":221,"hasResults":16,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":227,"enrollmentInfo":228,"targetDuration":230,"studyType":22,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":42},"100461063","uz-brussel-hrmc-registry-of-brugada-syndrome-100461063","NCT05283759","UZ Brussel HRMC Registry of Brugada Syndrome","UZ Brussel Heart Rhythm Management Center Monocentric Registry of Brugada Syndrome","HRMCBrS","Inclusion Criteria:\n\n* Brugada syndrome diagnosis\n\nExclusion Criteria:\n\n* Other diagnosis different from Brugada syndrome","100 Years",{"count":229,"type":21},2000,"30 Years","The monocentric UZB registry for Brugada registry is intended to collect all data on patients affected by Brugada syndrome at UZ Brussel hospital (UZB).",[26],"2022-03-12",{"date":235,"type":34},"2022-03-17",{"date":237,"type":34},"1992-01-01",{"date":239,"type":21},"2032-01-01",{"name":241,"class":41},"Universitair Ziekenhuis Brussel"]